Elevated Endogenous Psychedelic Bufotenine in the Urine of Patients Diagnosed With a Mental Illness: A Systematic Review.
Cureus May 20, 2025 DOI: 10.7759/cureus.84510 (opens in new tab) via PubMed Central
Summary
AI-generated from the abstractA systematic review examined whether patients diagnosed with a mental illness have elevated levels of the endogenous psychedelic compound bufotenine in their urine. The review found that bufotenine levels are higher in the urine of individuals with certain psychiatric disorders compared to healthy controls, suggesting a potential link between this neurochemical and mental health diagnoses. However, the evidence is limited by small sample sizes and methodological variability across studies, indicating that bufotenine may serve as a biomarker for some mental illnesses, but further research is needed to confirm these findings.
Study at a glance
| Characteristics | Systematic review Peer reviewed |
|---|---|
| Population | Patients diagnosed with a mental illness |
| Keywords | Bufotenine Natural psychedelic compound Mental illness Mental health diagnoses Psychiatric disorders |
| Citations | 1 |
| Key finding | Elevated levels of bufotenine in urine are associated with certain mental health diagnoses, but the evidence is limited and requires further investigation. |
Abstract
Elevated Endogenous Psychedelic Bufotenine in the Urine of Patients Diagnosed With a Mental Illness: A Systematic Review.